Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

140,451 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Tolaney SM, et al. Among authors: wang h. Clin Cancer Res. 2022 Apr 14;28(8):1500-1506. doi: 10.1158/1078-0432.CCR-21-3276. Clin Cancer Res. 2022. PMID: 35121623 Free PMC article. Clinical Trial.
Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.
Tolaney SM, Toi M, Neven P, Sohn J, Grischke EM, Llombart-Cussac A, Soliman H, Wang H, Wijayawardana S, Jansen VM, Litchfield LM, Sledge GW. Tolaney SM, et al. Among authors: wang h. Clin Cancer Res. 2022 Oct 14;28(20):4587. doi: 10.1158/1078-0432.CCR-22-2874. Clin Cancer Res. 2022. PMID: 36239018 No abstract available.
Landscape of baseline and acquired genomic alterations in circulating tumor DNA with abemaciclib alone or with endocrine therapy in advanced breast cancer.
Goetz MP, Hamilton EP, Campone M, Hurvitz SA, Cortes J, Johnston S, Llombart-Cussac A, Kaufman PA, Toi M, Jerusalem G, Graham H, Wang H, Jansen VM, Litchfield LM, Martín M. Goetz MP, et al. Among authors: wang h. Clin Cancer Res. 2023 Oct 27. doi: 10.1158/1078-0432.CCR-22-3573. Online ahead of print. Clin Cancer Res. 2023. PMID: 37889120 Free article.
Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma.
Martín-Broto J, Pousa AL, Brohl AS, Van Tine BA, Powers B, Stacchiotti S, Blay JY, Hu JS, Oakley GJ 3rd, Wang H, Szpurka AM, Levy DE, Mo G, Ceccarelli M, Jones RL. Martín-Broto J, et al. Among authors: wang h. Mol Cancer Ther. 2021 Jan;20(1):132-141. doi: 10.1158/1535-7163.MCT-20-0441. Epub 2020 Nov 11. Mol Cancer Ther. 2021. PMID: 33177152 Free article. Clinical Trial.
Distinct CDK6 complexes determine tumor cell response to CDK4/6 inhibitors and degraders.
Wu X, Yang X, Xiong Y, Li R, Ito T, Ahmed TA, Karoulia Z, Adamopoulos C, Wang H, Wang L, Xie L, Liu J, Ueberheide B, Aaronson SA, Chen X, Buchanan SG, Sellers WR, Jin J, Poulikakos PI. Wu X, et al. Among authors: wang h, wang l. Nat Cancer. 2021 Apr;2(4):429-443. doi: 10.1038/s43018-021-00174-z. Epub 2021 Mar 1. Nat Cancer. 2021. PMID: 34568836 Free PMC article.
140,451 results
You have reached the last available page of results. Please see the User Guide for more information.